BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $36,115,000 | -10.6% | 562,283 | +7.9% | 1.57% | +4.2% |
Q1 2022 | $40,408,000 | -4.4% | 521,124 | +5.9% | 1.51% | -1.4% |
Q4 2021 | $42,258,000 | +29.7% | 492,287 | +21.5% | 1.53% | +12.6% |
Q3 2021 | $32,586,000 | +25.0% | 405,144 | +25.1% | 1.36% | +27.9% |
Q2 2021 | $26,076,000 | +0.5% | 323,924 | +5.3% | 1.06% | -8.9% |
Q1 2021 | $25,941,000 | +374.3% | 307,572 | +351.3% | 1.16% | +340.5% |
Q4 2020 | $5,469,000 | +7.8% | 68,159 | +8.0% | 0.26% | -6.7% |
Q3 2020 | $5,075,000 | +6.7% | 63,103 | +14.2% | 0.28% | +1.1% |
Q2 2020 | $4,756,000 | +5.5% | 55,243 | -0.5% | 0.28% | -10.0% |
Q1 2020 | $4,506,000 | -36.6% | 55,503 | -34.6% | 0.31% | -22.6% |
Q4 2019 | $7,102,000 | +40.5% | 84,926 | +47.0% | 0.40% | +30.9% |
Q3 2019 | $5,054,000 | +1737.8% | 57,779 | +1619.1% | 0.31% | +1435.0% |
Q2 2019 | $275,000 | -35.0% | 3,361 | -35.3% | 0.02% | -37.5% |
Q1 2019 | $423,000 | +23.7% | 5,196 | 0.0% | 0.03% | +23.1% |
Q4 2018 | $342,000 | -14.7% | 5,196 | 0.0% | 0.03% | -10.3% |
Q3 2018 | $401,000 | +2.6% | 5,196 | -1.9% | 0.03% | -3.3% |
Q2 2018 | $391,000 | +15.0% | 5,296 | +1.3% | 0.03% | +11.1% |
Q1 2018 | $340,000 | +18.9% | 5,229 | +18.1% | 0.03% | +17.4% |
Q4 2017 | $286,000 | +10.4% | 4,429 | +7.3% | 0.02% | +4.5% |
Q3 2017 | $259,000 | +13.1% | 4,129 | +9.3% | 0.02% | 0.0% |
Q2 2017 | $229,000 | – | 3,779 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |